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Introduction 
Glutathione S-transferases catalyze the conjugation of glutathione (GSH) to a variety of hydrophobic 
substrates, rendering them hydrophilic and facilitating their metabolic processing and secretion from 
the cell. GSTs are involved in major detoxification mechanisms of the cell from several xenobiotics and 
drugs. On the other hand, on the basis of the same detoxification mechanisms, cancer cells may 
acquire resistance by overexpressing GST activities, thus hampering the effectiveness of certain 
chemotherapeutic drugs and leading to chemotherapeutic resistant tumor cells. Several synthetic 
drugs and prodrugs exhibiting inhibition potency against GSTs have been proposed as strategies to 
overcoming multiple drug resistance (MDR) attributed to GST overexpression. In the pursuit of 
identifying new lead compounds as inhibitors against hGSTs involved in MDR we have used Structure 
Based Ligand Design techniques to generate in silico xanthone and benzophenone derivatives and 
performed extensive molecular docking and binding evaluation on the structure of hGSTA1-1. 
Molecular Modeling and Docking 
The structure of hGSTA1-1 in complex with ethacrynic acid and its glutathione conjugate (PDB code 
1GSE) was prepared with the Protein Preparation Wizard [1] in Maestro (Schrodinger, LLC, New York, 
NY). A grid including the tripeptide substrate glutathione was set up centered on ethacrynic acid. 
Ligands were docked flexibly using Glide SP [2, 3]. In order to study ligand binding in the presence of 
CDNB, another grid was set up including both the tripeptide substrate glutathione and CDNB, and in 
silico molecular docking was repeated. Forty different global molecular properties have been predicted 
for the compounds using QikProp (Schrodinger, LLC, New York, NY). Structural similarity of the 
compounds was studied using OpenEye Scientific Software, Santa Fe, NM. http://www.eyesopen.com. 
OMEGA 2.5.1.4 [4, 5] was used to generate molecular conformations, while ROCS 3.2.0.4 [6] and EON 
2.2.0.5 identified shape and electrostatic similarity, calculating the TanimotoCombo and 
EON_ET_combo measures respectively. 
Experimental Methods 
Expression and purification of hGSTA1-1 from recombinant E. coli cells. Enzyme expression was 
induced from E. coli BL21 (DE3) cells harboring the plasmid pOXO4-GSTA1 by addition of IPTG. The 
cells were disrupted by sonication and the intracellular enzyme was purified on an affinity 
chromatography column bearing immobilized glutathione. 
Screening of the benzophenone, N-carbonyl and xanthone analogues for hGSTA1-1 inhibition. 
Screening assays were implemented by mixing potassium phosphate buffer (100 mM, pH 6.5), 0.75 or 
2.5 μmol GSH (in water), 25 or 100 nmol test compound (in DMSO) and enzyme. The mixture was 
incubated at 25oC for 1 min prior to adding 0.3 or 1 μmol CDNB (in ethanol). The observed rate was 
used to calculate the remaining activity (%), taking as 100% initial activity value the rate observed after 
replacing the test compound by an equal volume of DMSO. 
Kinetic analysis using CDNB and GSH as a variable substrate, in order to determine inhibition 
modality and kinetic constants. Kinetic inhibition studies against hGSTA1-1 were implemented using 
CNDB (37.5-980 μM; GSH constant at 2.5 mM) and GSH (100-2500 μM; CDNB constant at 1 mM) as 
variable substrates in assay conditions as above. 
Xanthone Derivatives 
18 xanthone derivatives were synthesized and tested as potential inhibitors against the human 
isoenzyme GSTA1-1. 
Derivatives 7, 8, and 17 are by far the most potent inhibitors for hGSTA1-1 (Table 1). In silico 
modeling analysis indicated that derivatives 7 and 8 place the xanthone moiety in the pocket in 
parallel with the benzene rings of Phe220, Phe222, and Tyr9, while the bromine is located 3.5 Å (7) 
and 5.1 Å (8) away from the sulfhydryl group of GSH and at an even longer distance (4.8 Å for 7 and 
6.5 Å for 8) from the catalytically important Tyr9 (Figure 1). Derivative 7 competes with CDNB for the 
same binding site with a kinetically determined inhibition constant Ki(7) = 0.76 ± 0.18 μM. Molecular 
modeling analysis indicated that 17 can be accommodated in the substrate site with the aldehyde 
group positioned in a polar extension pocket formed by the carbonyl oxygens of residues Pro206 and 
Pro207, so as to form an H-bond interaction (3.2 Å) with the backbone carbonyl group of Pro206 
(Figure 1). Derivative 17 competes with CDNB for the same binding site with a kinetically determined 
inhibition constant Ki(17) = 1.69 ± 0.08 μM. 
Benzophenones 
11 2,2'-dihydroxybenzophenones and N-carbonyl analogues were synthesized and tested as 
potential inhibitors against the human isoenzyme GSTA1-1.  
 
On the basis of the screening experiments, compounds 6, 8, 14 and 16 were studied further by 
enzyme inhibition kinetics (Table 2). 
When using CDNB as a variable substrate, 
compounds 6 and 14 displayed purely 
competitive inhibition kinetics (Ki(6) = 1.47 
± 0.15 μM and Ki(14) = 0.38 ± 0.05 μM), 
competing with CDNB for the same 
binding site of the enzyme. 
In silico molecular docking analysis 
predicts that both inhibitors 6 and 14 
(Figure 2), clash with CDNB if attempting 
to accommodate at the catalytic site of 
hGSTA1-1 where CDNB binds. With GSH as 
a variable substrate, both compounds 6 
and 14 showed mixed inhibition kinetics, 
suggesting that inhibitors 6 and 14 may 
interact at a site other than the GSH-
binding site of hGSTA1-1, that site being 
partly the catalytic CDNB-binding site. 
With CDNB as a variable substrate, 
compound 8 has shown mixed inhibition 
kinetics with Ki(8) = 0.36 ± 0.11 μM. 
The predicted complexes enzyme-8 and 
enzyme-CDNB-8 are unreactive ones. 
However, at [8] > 0.5 μM a second 
molecule of 8 binds hGSTA1-1, hence 
intensifying the inhibitory effect. 
The in silico models predicted close 
proximity and interaction between the 
substrate CDNB and 8 (two H-bonds, 2.56 
and 2.76 Å) when both bound in the 
enzyme (Figure 3), suggesting interference 
of 8 with the enzyme’s catalytic function 
involving CDNB.  
With CDNB as a variable substrate, 
inhibitor 16 has shown mixed inhibition 
kinetics with Ki(16) = 1.75 ± 0.25 μM. 
16 binds at the free enzyme and the 
enzyme-CDNB complex, with a GSH 
molecule present on the complexes. 
In silico molecular docking shows CDNB at 
the catalytic primary site and 16 at a 
secondary binding site (Figure 3) in 
hGSTA1-1, producing a reactive quadruple 
complex, enzyme-GSH-CDNB-16. 
Biological assays with the derivatives 
7, 8, and 17 have been implemented 
using cell lysate derived from human 
colon adenocarcinoma cells (Caco-2 
cell line) and intact Caco-2 cells. 
With regard to derivatives 7 and 8: 
Their enzyme inhibiting ability has 
been dramatically decreased, 
indicating low selectivity of 7 and 8 
for GST. 
They functioned as cytotoxic agents 
with intact Caco-2 cells. 
With regard to derivative 17 its 
inhibitory ability was similar to that 
with purified enzyme, suggesting some 
degree of selectivity exhibited by 17 
and it has shown a substantially lower 
cytotoxic effect with intact Caco-2 cells 
compared with derivative 7. 
In conclusion, derivatives 7, 8, and 17 
have shown a high inhibitory potency 
toward hGSTA1-1, of which derivative 
17 was the only one to readily inhibit 
the enzyme in colon cancer cell lysate. 
Furthermore, all three derivatives 
were cytotoxic to Caco-2 cells, with 17 
being the least cytotoxic. Thus, the 
xanthone scaffold may be regarded as 
a pharmacophore for hGSTA1-1 and 
the three derivatives, especially 17, as 
potent precursors for the synthesis of 
new inhibitors and conjugate prodrugs 
for human GSTs. 
Table 1. Xanthone Derivatives 7, 8, and 17 as Human GSTA1-1 
Inhibitors (IC50 Values) and Cytotoxic Agents for Caco-2 Cells (LC50 
Values). 
Caco-2, human colon adenocarcinoma cell line; ND, not determined due to low 
enzyme inhibition at a derivative solubility limit in cell lysate (~10% inhibition at 
150 μM); -, no enzyme inhibition at 100 μM xanthone. aMean value of three 
enzyme activity assays (0.1 mM analogue; error ≤ 3%). bPredicted octanol/water 
partition coefficient. cFor the cell viability assays, the final percentage of DMSO in 
cultures was a limiting factor. For compound 8, the maximum concentration tested 
had to be restricted to 20 μM with 2% DMSO in culture. dquery (reference) 
molecule: Entry 17 
Figure 1. 
Low energy conformations of xanthone derivatives as predicted 
by in silico molecular docking. 
(a) Xanthone derivatives 7 and 8 are shown in light brown and beige, 
respectively, whereas the cosubstrate glutathione (GSH) is depicted in 
magenta. The bromine atom of derivative 7 interacts with the sulfhydryl group 
of GSH (3.5 Å). (b) Xanthone derivative 17 occupies part of the primary binding 
site of the enzyme. The OH group (in red) of derivative 17 forms an H-bond 
interaction with the backbone carbonyl group of Pro206 (3.2 Å). 
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Studying the cytotoxic activity of the inhibitor lead molecules with human colon adenocarcinoma cell 
line (Caco2). 
If low cytotoxicity was a desirable property for a lead compound to qualify for drug design, aiming to 
eventually produce an enzyme-targeting drug inhibitor, the N-acyl hydrazone analogue 16 appears as a 
good ‘lead structure’ since it combines a low cytotoxicity profile (LC50 > 400 μM) with high inhibitory 
potency against hGSTA1-1 (IC50 = 0.18 ± 0.02 μM).  
However, if one were looking for a lead structure conferring both good cytotoxicity and enzyme 
inhibition, a balanced choice would probably be the other N-acyl hydrazone analogue, 14 (LC50 = 87 ± 
1.9 μM and IC50 = 0.33 ± 0.05 μM). 
In conclusion, the N-acyl hydrazone analogues, 14 and 16, appear to be a better choice as leads, 
compared to the benzophenone analogues 6 and 8, since the former showed better characteristics as 
Caco2 cytotoxic agents and hGSTA1-1 inhibitors.  
Table 2. Behavior of benzophenones selected from screening 
experiments against hGSTΑ1-1 activity (IC50) and Caco2 cells (LC50).  
aMean value of three enzyme assays (25 μM analogue; error ≤ 3%). bPredicted 
octanol/water partition coefficient. cCompounds 6, 8, 14 and 16 showed mixed 
inhibition modality with the co-substrate GSH. dquery (reference) molecule: 14 
Figure 3.  
Low energy conformations of substrates CDNB, GSH and inhibitor 8 (a),(b) and 16 (c), (d) at the most probable binding 
sites of hGSTA1-1 as predicted by in silico molecular docking in the presence or not of CDNB. 
 (a) In the presence of CDNB, inhibitor 8 is bound close to CDNB (represented by dots), developing H-bonds (2.56 Å and 2.76 Å). (c) In the presence 
of CDNB, Inhibitor 16 is bound far enough from CDNB (represented by dots) permitting catalytic function, though at a lower rate. The co-substrate 
GSH is depicted in magenta, the S atom in yellow, N atoms in blue and O atoms in red. 
a b 
c d 
Figure 2.  
Low energy conformations of substrates CDNB, GSH and 
inhibitors 6 (a) and 14 (b) at the most probable binding sites of 
hGSTA1-1 as predicted by in silico molecular docking. 
(a) Both inhibitors (green ligands) partly occupy the catalytic site and clash 
with CDNB (represented by dots) when it is bound at the same site. GSH is 
depicted in magenta, the S atom in yellow, N atoms in blue and O atoms in red. 
a 
b 
Apparently, these locations are not close enough to allow interference of 16 to the catalytic function. 
With GSH as a variable substrate, both compounds 8 and 16, predictably, showed mixed inhibition 
kinetics 
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